BSc (Hons), PhD, Fellow of the Chartered Institute of Patent Attorneys, European Patent Attorney, Patent Attorney Litigator.
Mark is a Patent Attorney specialising in the life sciences, with experience in devising global patent strategies and challenging/defending patent rights at the Opposition Division and Board of Appeal of the European Patent Office.
His main areas of expertise include inventions in the fields of antibody technology, personalised medicine, genetic engineering, industrial enzymes and biochemistry.
Mark studied Microbiology and Virology at the University of Warwick and obtained a PhD in Molecular Cell Biology at the same university. His studies included research placements at AstraZeneca in the UK, and Novartis in Austria. He subsequently completed a two-year post-doctoral fellowship in Mammalian Molecular Biology at Imperial Cancer Research Fund (now Cancer Research UK) in Dundee. His research has been published in peer-reviewed journals including Journal of Biological Chemistry and Nature.
Mark joined Potter Clarkson in 2003 and became a Partner in 2011.
In 2014, he qualified as a Patent Attorney Litigator and was awarded a Higher Courts Litigation Certificate, allowing him to conduct litigation in the High Court and the Court of Appeal, in addition to having a right of audience in the Intellectual Property Enterprise Court.
Mark’s recent litigation experience includes the recent High Court and Court of Appeal successes in Stretchline Intellectual Properties Limited v. H&M Hennes & Mauritz Limited.
In 2005, Mark was awarded the Moss Prize for obtaining the highest overall mark in the foundation level patent examination papers.
Mark has been listed in the Legal 500 as “notable for expertise in the biotechnology sector” and in 2017 was listed as an IP Star by Managing Intellectual Property.